Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) have entered a global license agreement for mesothelin-directed CAR T-cell therapies targeting solid tumors. This collaboration involves the development candidate ATA3271 and an autologous version, ATA2271. Atara will oversee IND-enabling studies while Bayer manages the IND submission and clinical development. Atara receives an upfront payment of $60 million and can earn up to $610 million in milestones plus royalties on net sales. This partnership aims to enhance the development of off-the-shelf CAR T-cell therapies for challenging cancer types.
Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced participation in two upcoming virtual conferences. The Stifel 2020 Virtual Healthcare Conference is set for November 18, 2020, featuring a fireside chat with CEO Pascal Touchon. The Evercore ISI 3rd Annual Virtual HealthCONx Conference will take place on December 2, 2020, with chats including Pascal Touchon and Jakob Dupont, Global Head of Research and Development. Both events will be accessible via live webcasts on the company's website, with archived replays available for 14 days.
Atara Biotherapeutics (Nasdaq: ATRA) announced promising 15-month safety and efficacy data for ATA188, a treatment for progressive multiple sclerosis (MS), presented at the European Charcot Foundation's 28th Annual Meeting. In a Phase 1a study, 50% of patients showed sustained disability improvement, indicating a potential treatment effect. Atara plans to enhance its investment in the ATA188 program, expanding the randomized controlled trial to at least 64 patients and focusing on disability improvement as the primary endpoint. This treatment addresses a significant unmet need in MS.
Atara Biotherapeutics (Nasdaq: ATRA) announced the preclinical evaluation of ATA3271, an allogeneic EBV CAR T-cell therapy targeting mesothelin for solid tumors. The data, presented at the SITC 2020, demonstrate potent antitumor activity of ATA3271 in both in vitro and in vivo settings, with no evident toxicities. The therapy retained function despite high PD-L1 expression in tumor environments. Additionally, the FDA accepted an IND application for another therapy, ATA2271. These advancements signal a step forward in Atara's commitment to transformative cancer therapies.
Atara Biotherapeutics (Nasdaq: ATRA) reported its Q3 2020 financial results, revealing a net loss of $74.3 million, or $0.92 per share. Despite a cash balance of $327.2 million sufficient to fund operations into 2022, R&D expenses increased to $59.9 million due to expanding clinical activities. Notably, the interim analysis of tab-cel® for relapsed-refractory EBV+ PTLD showed a 50% objective response rate. Atara plans to submit a BLA for tab-cel® by year-end 2020 and an EU MAA in H2 2021, further advancing their allogeneic T-cell therapies.
Atara Biotherapeutics (ATRA) will release its Q3 2020 financial results on November 9, 2020, after market close. The company, known for its innovative T-cell immunotherapy, will host a conference call at 4:30 p.m. EST to discuss the results and provide a corporate update. Analysts and investors can join the call via designated phone numbers or access the live audio webcast on Atara's website. The company aims to deliver life-changing therapies for diseases like solid tumors and hematologic cancers through its EBV T-cell platform.